Melatonin Prolonged Release

@article{LysengWilliamson2012MelatoninPR,
  title={Melatonin Prolonged Release},
  author={K. Lyseng-Williamson},
  journal={Drugs & Aging},
  year={2012},
  volume={29},
  pages={911-923}
}
Melatonin prolonged release (PR) 2 mg is approved for the treatment of primary insomnia characterized by poor sleep quality in patients aged ≥55 years in the EU and elsewhere. Patients may receive treatment with melatonin PR for up to 13 weeks. Production of endogenous nocturnal melatonin, which helps regulate circadian rhythm, may be decreased in older adults. Administration of melatonin PR 2 mg 1–2 h before bedtime mimics the natural secretion pattern of melatonin, thereby leading to… Expand
34 Citations

Paper Mentions

Interventional Clinical Trial
The main aim of this study was to evaluate the effectiveness of melatonin in prevention of radiation induced oral mucositis clinically and biochemically.  
ConditionsOral Mucositis (Ulcerative) Due to Radiation
InterventionDietary Supplement, Drug, Other
Sleep Disorders and Melatonin
Tasimelteon for treating non-24-h sleep-wake rhythm disorder
  • 2
...
1
2
3
4
...

References

SHOWING 1-10 OF 45 REFERENCES
Improvement of sleep quality in elderly people by controlled-release melatonin
  • 460
  • Highly Influential
  • PDF
Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes
  • 189
  • Highly Influential
  • PDF
Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs.
  • 69
  • Highly Influential
  • PDF
New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists
  • R. Hardeland
  • Medicine
  • Neuropsychiatric disease and treatment
  • 2009
  • 81
  • PDF
Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy.
  • 140
  • PDF
The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia
  • 86
  • Highly Influential
Prolonged‐release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects
  • 209
  • Highly Influential
  • PDF
Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response
  • 72
  • Highly Influential
  • PDF
Role of the Melatonin System in the Control of Sleep
  • 120
  • Highly Influential
  • PDF
...
1
2
3
4
5
...